Sino Biopharmaceutical Intangible Assets

Sino Biopharmaceutical (SBHMY) currently reports a intangible assets of $3.6B as of December 2025. That compares with $2.1B in the prior-year period — up 65.8% year over year. Use the charts on this page to explore Sino Biopharmaceutical's intangible assets history and peer comparisons.

Sino Biopharmaceutical's intangible assets increased from $2.1B to $3.6B — a 65.8% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sino Biopharmaceutical reported $3.6B in intangible assets as of December 2025. That compares with $2.1B in the prior-year period — up 65.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current intangible assets of $3.6B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sino Biopharmaceutical, and consider following SBHMY for alerts when major investors trade the stock.

Sino Biopharmaceutical is classified in the Healthcare sector. On intangible assets, it currently shows $3.6B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SBHMY with unrelated industries.